Suyash Prasad's most recent trade in Taysha Gene Therapies Inc was a trade of 8,956 Common Stock done at an average price of $3.8 . Disclosure was reported to the exchange on July 5, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 3.79 per share. | 05 Jul 2022 | 8,956 | 530,589 | - | 3.8 | 33,943 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 3.51 per share. | 05 Jul 2022 | 3,905 | 539,545 | - | 3.5 | 13,707 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 3.53 per share. | 29 Jun 2022 | 23,923 | 543,450 | - | 3.5 | 84,448 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 3.72 per share. | 29 Jun 2022 | 13,892 | 567,373 | - | 3.7 | 51,678 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 3.81 per share. | 29 Jun 2022 | 12,324 | 581,265 | - | 3.8 | 46,954 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2022 | 40,325 | 40,325 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 23.74 per share. | 29 Jun 2021 | 35,056 | 637,533 | - | 23.7 | 832,229 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 21.12 per share. | 29 Jun 2021 | 19,706 | 593,589 | - | 21.1 | 416,191 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 21.42 per share. | 29 Jun 2021 | 13,374 | 619,997 | - | 21.4 | 286,471 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 22.44 per share. | 29 Jun 2021 | 6,202 | 613,795 | - | 22.4 | 139,173 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 24.46 per share. | 29 Jun 2021 | 3,862 | 633,671 | - | 24.5 | 94,465 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 23.70 per share. | 29 Jun 2021 | 500 | 613,295 | - | 23.7 | 11,850 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Sale of securities on an exchange or to another person at price $ 25.19 per share. | 29 Jun 2021 | 300 | 633,371 | - | 25.2 | 7,557 | Common Stock |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | 28 Sep 2020 | 3,844 | 672,589 | - | - | Common Stock | ||
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | 28 Sep 2020 | 3,529 | 0 | - | - | Series B Preferred Stock | ||
| Taysha Gene Therapies Inc | Suyash Prasad | CMO and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2020 | 668,745 | 668,745 | - | - | Common Stock |